Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $486000.0.

  • Biodesix's Change in Accured Expenses fell 2186.5% to $486000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 26685.63%. This contributed to the annual value of $1.6 million for FY2024, which is 21910.33% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's Change in Accured Expenses is $486000.0, which was down 2186.5% from $2.3 million recorded in Q2 2025.
  • Biodesix's Change in Accured Expenses' 5-year high stood at $3.3 million during Q2 2023, with a 5-year trough of -$5.7 million in Q1 2021.
  • Its 5-year average for Change in Accured Expenses is -$271736.8, with a median of $191000.0 in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 77024.5% in 2021, then surged by 289724.77% in 2023.
  • Biodesix's Change in Accured Expenses (Quarter) stood at $1.8 million in 2021, then tumbled by 106.91% to -$127000.0 in 2022, then surged by 698.43% to $760000.0 in 2023, then surged by 122.89% to $1.7 million in 2024, then tumbled by 71.31% to $486000.0 in 2025.
  • Its Change in Accured Expenses was $486000.0 in Q3 2025, compared to $2.3 million in Q2 2025 and -$1.9 million in Q1 2025.